Tatva Chintan Pharma Chem Annualised Returns
Tatva Chintan Pharma Chem Annualised Returns
Tatva Chintan Pharma Chem Share Price Today
Tatva Chintan Pharma Chem Share Price Today
As of 22 Oct 2026, Tatva Chintan Pharma Chem share price is ₹1764.5. The stock opened at ₹1820 and had closed at ₹1890.1 the previous day. During today’s trading session, Tatva Chintan Pharma Chem share price moved between ₹1,760.00 and ₹1,843.50, with an average price for the day of ₹1801.75. Over the last 52 weeks, the stock has recorded a low of ₹1,044.10 and a high of ₹2,113.60. In terms of performance, Tatva Chintan Pharma Chem share price has increased by 37.9% over the past six months and has increased by 52.01% over the last year.
Tatva Chintan Pharma Chem Stock Performance
Tatva Chintan Pharma Chem Share Price Chart
Tatva Chintan Pharma Chem Share Price Chart
Tatva Chintan Pharma Chem Company background
Tatva Chintan Pharma Chem Limited was formerly incorporated as Tatva Chintan Pharma Chem Private Limited on 12 June 1996. The status of the Company converted from Private Limited into a Public Limited Company from 27 January 2021 and the name of Company changed from Tatva Chintan Pharma Chem Private Limited to Tatva Chintan Pharma Chem Limited. The Company is an integrated specialty chemicals manufacturer with three decades of experience in complex and applicationled chemistry. It is primarily engaged in manufacturing, distribution and selling of specialty chemicals i.e., Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC). These products cater to diverse industries such as pharmaceuticals, agrochemicals, automotive, electronics, resins and polymers, flavours and fragrances, personal care and disinfectants, oil field and energy storage.The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located closer to the Hazira Port. These units provide cost and logistics advantage through a seamless export and import operations. The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved RD centre at its Vadodara facility where qualified and experienced inhouse RD team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with stateoftheart instrumentation.In 2004, the Company received licence from the FDA, Gujarat at its Ankleshwar manufacturing plant.In 2007, the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity.In 2011, the Company started commercial manufacturing of Structure Directing Agents (SDA).In 2015, the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise, Customs Service Tax, Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL.In 2016, the Company was accorded the status of a twostar export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry (MoCI), Government of India (GoI).In 2017, manufacturing plant was established in Dahej, Gujarat.Tatva Chintan Europe BV, was incorporated as wholly owned Subsidiary of the Company in year 2019.In FY 201920, the Companys Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower byproducts and waste generation in chemical processes.Additionally, the Company participated in the Together for Sustainability initiatives whereby sustainability sourcing practices of chemical suppliers, like ecological and social aspects were assessed. Under this initiative, the Company involved Ecovadis to audit sustainability practices and performance, the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business. In 2021, the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively.The Company launched its Initial Public Offer cum Offer for Sale of 46,16,804 Equity Shares by raising funds from public aggregating to Rs 500 Crore, comprising a Fresh Issue of 20,77,562 Equity Shares aggregating to Rs 225 Crore and an Offer for Sale of 25,39,242 Equity Shares aggregating to Rs 275 Crore in July, 2021. The Company commenced commercial production from the newly expanded facility at Dahej SEZ. With this, the installed reactor capacity increased to 500 KL from 294 KL and assembly lines increased from 27 to 39 in 202324. It has started production at Distillation Plant in 2026.
Tatva Chintan Pharma Chem Financial Highlights
For Q2 FY2026–2027, Tatva Chintan Pharma Chem's revenue reached ₹219.07 crore and profit touched at ₹21.45 crore. As of 22 October 2026, Tatva Chintan Pharma Chem’s market capitalization reached at ₹4,421.33 crores. Shareholding as of 22 October 2026 shows promoters holding 72%, with FIIs at 4.4%, DIIs at 3.2%, and public at 20.4%.
Tatva Chintan Pharma Chem Fundamental
Market Cap (in crs)
4,421.33
Face Value
10
Turnover (in lacs)
1,147.63
Key Metrics
Tatva Chintan Pharma Chem Key Financials
View moreTatva Chintan Pharma Chem Result Highlights
-
Tatva Chintan Pharma Chem reported a 2.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 0.6%.
-
Its expenses for the quarter were up by 1.5% QoQ and 7.5% YoY.
-
The net profit decreased 121.2% QoQ and decreased 96.0% YoY.
-
The earnings per share (EPS) of Tatva Chintan Pharma Chem stood at 0.1 during Q3FY25.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Tatva Chintan Pharma Chem Technical Analysis
Delivery & Volume
Delivery Volume %
Day
20.90%
Week
27.10%
Month
35.70%
Resistance & Support
Tatva Chintan Pharma Chem Peer comparison
CompareIndex Name | Market Price |
|---|---|
1,886.00 -38.40 (-2.00%)▼ | |
51.86 -0.87 (-1.65%)▼ | |
585.45 -6.15 (-1.04%)▼ | |
3,445.50 +50.50 (+1.49%)▲ | |
158.62 -2.38 (-1.48%)▼ | |
703.20 -4.80 (-0.68%)▼ |
Tatva Chintan Pharma Chem Latest News
Tatva Chintan Pharma Chem Share Price FAQs
Tatva Chintan Pharma Chem share price is ₹1764.5 in NSE and ₹1716.65 in BSE as on 22/10/2026.
Tatva Chintan Pharma Chem share price in the past 1-year return was 25.39. The Tatva Chintan Pharma Chem share hit a 1-year low of Rs. 1044.1 and a 1-year high of Rs. 2113.6.
The market cap of Tatva Chintan Pharma Chem is Rs. 4421.33 Cr. as of 22/10/2026.
The PE ratios of Tatva Chintan Pharma Chem is 86.61 as of 22/10/2026.
The PB ratios of Tatva Chintan Pharma Chem is 5.64 as of 22/10/2026
The Mutual Fund Shareholding in Tatva Chintan Pharma Chem was 2.87% at the end of 22/10/2026.
You can easily buy Tatva Chintan Pharma Chem shares in Kotak Neo by opening a demat account and getting the KYC documents verified online.
The 52-week high and low of Tatva Chintan Pharma Chem share price is ₹2113.6 and ₹1044.1 as of 22/10/2026.
Please be aware that Tatva Chintan Pharma Chem stock prices are subject to continuous fluctuations due to various factors.